Correction of a recurrent pathogenic variant in methylmalonic acidemia using adenine base editing

This study demonstrates that adenine base editing using lipid nanoparticle-delivered mRNA and optimized guide RNA can efficiently and specifically correct the recurrent pathogenic c.556C>T (R186W) variant in the MMAB gene in hepatocytes, establishing a promising therapeutic platform for treating methylmalonic acidemia.

The Gist

Imagine your body is a massive, bustling factory. Inside this factory, there are specialized assembly lines that break down the food you eat (specifically certain proteins) into useful energy and building blocks.

The Problem: A Broken Machine
In a condition called Methylmalonic Acidemia (MMA), one of these assembly lines is broken. Specifically, the machine responsible for processing a specific type of protein is jammed. Because the machine is broken, toxic waste (called methylmalonic acid) starts piling up in the factory. This waste is like a chemical spill that poisons the workers, causing severe illness, brain damage, and even death.

The most common cause of this specific type of jam is a tiny typo in the factory's instruction manual (our DNA). A single letter in the code has been changed from a "C" to a "T," which tells the machine to build a useless part instead of a working one. This specific typo is called the R186W variant.

Currently, the only way to fix this is a "liver transplant." Think of this as tearing down the entire old factory and building a brand new one from scratch. It works, but it's risky, expensive, and you have to wait for a donor.

The Solution: The "Correction Pen"
The scientists in this paper didn't want to tear down the factory. Instead, they wanted to use a high-tech correction pen to fix the single typo in the instruction manual while the factory was still running.

They used a technology called Adenine Base Editing.

• The Pen: This is a molecular tool (an enzyme) that can find a specific letter in the DNA and change it back to the correct one without cutting the whole strand of DNA.
• The Target: They aimed specifically at the "C" that had been wrongly changed to a "T," turning it back into a "C" so the machine works again.

The Journey to the Perfect Tool
The scientists didn't just grab any pen; they had to find the perfect one. Here is how they did it:

1. Testing Different Pens: They tried out many different versions of the base editor (like trying different brands of pens) to see which one could find the typo most accurately. They found that a specific combination, which they named SpG-ABE8e, was the best at finding the R186W typo.
2. Stopping the "Scribbles": Sometimes, these correction pens are a bit messy. They might fix the typo you wanted, but they also accidentally scribble on nearby letters (called "bystander editing"). To stop this, the scientists created a special "Hybrid Guide RNA."
   • Analogy: Imagine the guide RNA is a GPS for the pen. The standard GPS was a bit vague and might take the pen to the wrong house nearby. The new "Hybrid GPS" has a very precise route, ensuring the pen only visits the exact house with the typo and ignores the neighbors.
3. Checking for Mistakes: Before they could use this on people, they had to make sure the pen wouldn't accidentally fix the wrong page in the manual elsewhere in the factory. They ran a massive security check (called ONE-seq) and found that their new Hybrid GPS made the pen incredibly safe, with almost no accidental scribbles.

The Delivery Truck
Once they had the perfect pen and the perfect GPS, they needed a way to get them into the liver cells. They used Lipid Nanoparticles (LNPs).

• Analogy: Think of the LNPs as tiny, biodegradable delivery trucks. They wrap the pen and the GPS inside a fatty bubble. When injected into the bloodstream, these trucks travel straight to the liver (the factory), knock on the door, and drop off the repair crew.

The Results
When they tested this in human liver cells in a lab:

• The delivery trucks arrived successfully.
• The repair crew found the typo and fixed it.
• The "messy scribbles" were almost completely gone.
• The cells started producing the working machine again.

Why This Matters
This isn't just about fixing one disease; it's about proving a new way of thinking.

• For MMA: This offers a potential one-time cure for patients with this specific genetic typo, avoiding the need for a liver transplant.
• For the Future: The scientists believe this "platform" can be adapted for many other rare genetic diseases. Just like a master key can be cut to fit many different locks, this base-editing platform could be tweaked to fix different typos in different diseases.

In Summary
The scientists developed a precise, safe, and efficient way to use a "molecular correction pen" delivered by "nanotrucks" to fix a single-letter typo in the DNA of liver cells. This could turn a life-threatening genetic disease into a manageable condition, or even cure it, without the need for a full organ transplant.

Technical Summary

1. Problem Statement

Methylmalonic Acidemia (MMA) is a rare, recessive genetic disorder caused by defects in the MMUT gene or the MMAB gene. The MMAB gene encodes a protein essential for processing the vitamin B12 cofactor required by the methylmalonyl-CoA mutase enzyme.

• Specific Target: The study focuses on the recurrent, severe, infantile-onset pathogenic variant MMAB c.556C>T (p.Arg186Trp or R186W). This variant accounts for a large proportion of MMAB disease alleles and results in a complete loss of protein function.
• Current Limitations: Standard care involves strict dietary restriction of propiogenic amino acids and high-dose vitamin B12, which is often ineffective. Liver transplantation is the only curative option for severe cases but is limited by donor availability, surgical risks, and the need for patient growth.
• Therapeutic Goal: To develop a durable, one-time gene editing therapy that corrects the R186W variant back to the wild-type sequence in the liver, restoring enzyme function and reducing toxic metabolite accumulation.

2. Methodology

The researchers employed a systematic optimization strategy using Adenine Base Editors (ABEs) delivered via Lipid Nanoparticles (LNPs) to hepatocytes.

• Cell Model: Human HuH-7 hepatoma cells were transduced with a lentiviral vector containing the MMAB R186W variant sequence. PAH (Phenylketonuria) variants (P281L and R408W) served as positive controls due to previously validated editing solutions.
• Editor and Guide RNA (gRNA) Screening:
  • Tested various ABEs (ABE8.8, ABE8.20, ABE8e) with different editing windows.
  • Screened seven gRNAs (gRNA3–gRNA9) tiling the R186W site.
  • Selection: The combination of SpG-ABE8e and gRNA8 showed the highest initial corrective efficiency.
• Safety Optimization (Off-target & Bystander Reduction):
  • Editor Variant: Switched to ABE8e-V106W (specifically SpG-ABE8e-V106W and later NGC-ABE8e-V106W) to eliminate gRNA-independent off-target RNA/DNA editing.
  • Hybrid gRNAs: Developed "hybrid" gRNA configurations (hyb16 and hyb17) containing DNA nucleotide substitutions in the spacer sequence. These modifications are designed to reduce bystander editing (unwanted edits to nearby adenines) and off-target genomic editing.
  • Delivery: Transitioned from plasmid transfection to mRNA/gRNA delivery using LNPs (formulated with SM-102 ionizable lipid) to mimic a therapeutic clinical setting.
• Validation Assays:
  • ONE-seq: A homology-dependent biochemical assay to identify potential off-target sites across the genome.
  • rhAmpSeq: Targeted amplicon sequencing to validate editing at top candidate off-target sites.
  • Dose-Response: Evaluated editing efficiency in HuH-7 cells using varying concentrations of LNPs.

3. Key Contributions

• Identification of a Clinical-Grade Editing Strategy: Established a specific ABE/gRNA combination (NGC-ABE8e-V106W + hybrid gRNA8) capable of correcting the MMAB R186W variant with high precision.
• Optimization of Specificity: Demonstrated that hybrid gRNAs (specifically hyb16) significantly reduce both bystander editing (unwanted edits at the target locus) and off-target editing (edits at genomic sites with sequence similarity) compared to standard gRNAs.
• Platform Validation: Validated the use of LNP-mediated mRNA delivery for liver-targeted base editing in a disease-relevant context, building on previous work with CPS1 and PAH deficiencies.
• Pathway to "Umbrella" Trials: Proposed a framework for treating multiple rare metabolic diseases using a single platform approach, potentially accelerating regulatory approval for personalized gene editing therapies.

4. Key Results

• High Corrective Efficiency: The SpG-ABE8e-V106W/gRNA8 combination achieved corrective editing efficiency comparable to the gold-standard PAH P281L correction.
• Superiority of Hybrid gRNAs:
  • The hyb16 configuration of gRNA8, when paired with NGC-ABE8e-V106W, resulted in a substantial reduction in bystander editing.
  • This led to a higher proportion of "correction-only" events (restoring wild-type without altering neighboring bases) compared to the standard gRNA.
  • The editing efficiency of the optimized hybrid system surpassed that of the validated PAH P281L solution.
• Reduced Off-Target Activity:
  • ONE-seq Analysis: Standard gRNA8 identified 424 candidate off-target sites (score > 0.01). The hybrid configurations (hyb16/hyb17) reduced this to 125–127 sites.
  • rhAmpSeq Validation: Targeted sequencing of the top off-target sites (OT-11, OT-22, OT-92) confirmed that hybrid gRNAs significantly reduced editing at these loci compared to the standard gRNA.
• LNP Delivery Efficacy:
  • LNPs encapsulating NGC-ABE8e-V106W mRNA and the hyb16 gRNA achieved near-saturation editing in HuH-7 cells.
  • The calculated EC50 was approximately 30 ng/mL, indicating potent delivery suitable for in vivo application.

5. Significance and Future Implications

• Therapeutic Potential: This study provides a robust preclinical foundation for a gene editing therapy for patients with MMAB-related MMA carrying the R186W variant. Restoring even 10–20% of hepatic enzyme activity is predicted to correct disease phenotypes.
• Selective Advantage: The authors note that in mouse models of MMA, corrected hepatocytes exhibit a selective growth advantage. If this holds true in humans, the therapeutic threshold for editing efficiency could be very low, making LNP-mediated editing highly viable.
• Scalability: While focused on one variant, the approach supports a "platform" strategy. Many other pathogenic variants in MMAB and other organic acidemias are C>T or G>A substitutions amenable to adenine base editing.
• Regulatory Pathway: The work supports the feasibility of "umbrella" clinical trials where patients with different variants of the same disease (or related diseases) are treated under a master protocol, potentially accelerating the approval of personalized gene therapies for rare metabolic disorders.

In conclusion, this paper demonstrates a highly optimized, safe, and efficient adenine base editing strategy for correcting a major cause of methylmalonic acidemia, moving the field closer to a curative, non-transplant treatment for this devastating genetic disease.